scholarly journals Transforming Growth Factor-α Expression in the Anterior Pituitary Gland: Regulation by Epidermal Growth Factor and Phorbol Ester in Dispersed Cells

1989 ◽  
Vol 3 (6) ◽  
pp. 976-983 ◽  
Author(s):  
Susan G. Mueller ◽  
Michael S. Kobrin ◽  
Andrew J. Paterson ◽  
Jeffrey E. Kudlow
1994 ◽  
Vol 141 (3) ◽  
pp. 547-554 ◽  
Author(s):  
E L Finley ◽  
J S King ◽  
J S Ramsdell

Abstract Transforming growth factor-α (TGF-α) is a growth-regulatory peptide produced by a variety of transformed and non-transformed cells. Among non-transformed cells, TGF-α has been identified in the prolactin (PRL)- and GH-secreting cells of the bovine anterior pituitary gland. In this report, we have examined the expression of TGF-α in human anterior pituitary glands by Western analysis and immunohistochemistry. For the Western analysis, human pituitary glands were extracted in acid/ethanol, an acetic acid-soluble fraction was ether-precipitated and dialysed, and TGF-α was partially purified by C18 chromatography. TGF-α was then identified by immunostaining of Western transfers. Anterior pituitary extracts exhibited a major band(s) migrating at 19 kDa that was immunoreactive with a monoclonal antibody directed against the mature TGF-α. However, no evidence of the fully processed 6 kDa TGF-α was observed. We next identified TGF-α by immunohistochemistry. Using both monoclonal and polyclonal antibodies, specific immunoreactivity was identified in a population of secretory cells in the anterior pituitary gland. Using antibodies specific for the COOH and NH3 terminals of the TGF-α precursor, a comparable number of TGF-α-positive cells were found to contain TGF-α precursor sequences. These results indicate that the 19 kDa form of TGF-α expressed in the human pituitary gland may exist as the transmembrane form. We next sought to determine which cells express TGF-α in a human male pituitary gland. On frontal sections, TGF-α-immunopositive cells were evenly distributed in a manner and number indistinguishable from GH-immunopositive cells. By contrast, PRL-immunopositive cells in midfrontal sections were largely restricted to the lateral wings and extended dorsally to the neural lobe. TGF-α was positively co-localized to GH-immunopositive cells but not in PRL-immunopositive cells by immunostaining of consecutive sections. TGF-α-immunopositive cells were also immunopositive for the epidermal growth factor receptor, indicating that TGF-α has the capacity for autocrine action in the human pituitary gland. These results indicate that TGF-α is expressed in the human anterior pituitary gland and it is not proteolytically processed into the mature 6 kDa form. In addition, immunohistochemistry of an adult male human pituitary gland indicates that TGF-α is expressed in somatotropes and has the capacity for autocrine action. Journal of Endocrinology (1994) 141, 547–554


2004 ◽  
Vol 128 (1) ◽  
pp. 68-70
Author(s):  
Yun-Cai Cai ◽  
Victor Roggli ◽  
Eugene Mark ◽  
Philip T. Cagle ◽  
Armando E. Fraire

Abstract Background.—Growth factors such as transforming growth factor α (TGF-α) and epidermal growth factor receptor (EGFR) play an important role in cell proliferation. The immunohistochemical expression of these factors has been extensively studied in malignant tumors including mesothelioma. However, the comparative expression of these growth factors in mesothelioma and reactive mesothelial proliferations has been less well studied. Objective.—To evaluate the possible role of TGF-α and EGFR in the clinically important distinction between reactive mesothelial proliferations and malignant mesothelioma. Methods.—The expression of TGF-α and EGFR was studied in 39 cases of mesothelioma and 30 cases of reactive mesothelial proliferations by means of immunohistochemistry. Results.—Fourteen (70%) of 20 reactive mesothelial proliferations tested and 29 (76%) of 38 mesotheliomas tested expressed TGF-α. One (3%) of 30 reactive mesothelial proliferations and 17 (45%) of 39 mesotheliomas expressed EGFR. Conclusions.—These results suggest an up-regulation of EGFR in mesothelioma as compared with reactive mesothelial proliferations. This up-regulation further suggests a possible use of EGFR as an adjunct immunohistochemical test in the differential diagnosis of mesothelioma and reactive mesothelial proliferations.


Sign in / Sign up

Export Citation Format

Share Document